Agentix Corp (AGTX) is a clinical-stage biopharmaceutical company developing a drug candidate targeting peripheral cannabinoid receptor 1 (CB1) to treat Type 2 diabetes, obesity, and fatty liver disease. The company generates no product revenue and funds operations through external financing while advancing a licensed compound through pre-clinical and early clinical stages. Through its wholly-owned subsidiary Applied BioPharma LLC, Agentix holds a worldwide, royalty-bearing, exclusive license acquired from National Health Research Institutes (Taiwan) covering pyrazole compounds that act as peripherally restricted CB1 antagonists. The license, effective May 21, 2021, carries milestone payment obligations tied to Phase I, Phase II, Phase III, and regulatory approvals across the FDA, EMA, and other agencies, plus additional payments upon reaching $100 million in worldwide sales. The company is classified as a smaller reporting company and carries a stockholders' deficit as of March 31, 2025. Riazul (Rehan) Huda serves as Chief Executive Officer, Chief Financial Officer, and Director, appointed July 2, 2020, and received zero cash or equity compensation in both FY2025 and FY2024.

Revenue model

No product revenue reported. The company holds a royalty-bearing exclusive license and owes milestone payments to its licensor; it has not yet generated commercial sales as of the fiscal year ended March 31, 2025.

Products and services

One licensed drug candidate: a peripherally restricted CB1 receptor antagonist (pyrazole compound class) targeting Type 2 diabetes, obesity, and nonalcoholic fatty liver disease. The compound has completed preliminary pre-clinical and in vivo testing and is positioned for Phase I clinical trials as disclosed in the 10-K filed 2025-07-16.

Customers and end markets

No commercial customers as of March 31, 2025. Target end markets are patients with Type 2 diabetes, obesity, and fatty liver disease, subject to FDA and international regulatory approval.

Value-chain role

Licensor-dependent drug developer. Agentix in-licensed the core technology from National Health Research Institutes and is responsible for clinical development, regulatory submissions, and eventual commercialization. The company relies on third-party manufacturing in FDA-approved facilities and external consulting (Salman Hoda Pharma Consulting, Inc.) per filings.

Geographic exposure

License covers worldwide rights. The company is incorporated in Nevada. Regulatory strategy references FDA (United States), EMA (European Union), and PMDA (Japan) approval pathways as disclosed in the 10-K filed 2025-07-16.

Competitors

Pfizer (otenabant program, terminated), Merck (taranabant program, terminated), Sanofi (rimonabant program, terminated)

Source: SEC 10-K, filed 2025-07-16

Industry: Biological Products, (No Diagnostic Substances)